Fluidigm (FLDM) Stock Rating Lowered by BidaskClub

Fluidigm (NASDAQ:FLDM) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday, BidAskClub reports.

A number of other analysts also recently issued reports on FLDM. Zacks Investment Research downgraded Fluidigm from a “buy” rating to a “hold” rating in a research report on Tuesday, January 1st. ValuEngine upgraded Fluidigm from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Janney Montgomery Scott upgraded Fluidigm from a “neutral” rating to a “buy” rating in a research report on Thursday, January 3rd. Piper Jaffray Companies raised their price target on Fluidigm from $10.00 to $14.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. Finally, BTIG Research started coverage on Fluidigm in a research report on Wednesday, March 13th. They issued a “buy” rating and a $15.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $14.00.

FLDM stock opened at $12.83 on Friday. Fluidigm has a fifty-two week low of $4.65 and a fifty-two week high of $14.90. The company has a quick ratio of 3.04, a current ratio of 3.38 and a debt-to-equity ratio of 2.39. The firm has a market capitalization of $885.13 million, a P/E ratio of -16.04 and a beta of 2.43.

Fluidigm (NASDAQ:FLDM) last posted its earnings results on Thursday, February 7th. The medical research company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. The firm had revenue of $32.33 million during the quarter, compared to analyst estimates of $30.55 million. Fluidigm had a negative net margin of 52.24% and a negative return on equity of 71.42%. Analysts predict that Fluidigm will post -0.58 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the company. Quantamental Technologies LLC bought a new stake in shares of Fluidigm during the fourth quarter worth $61,000. United Services Automobile Association bought a new stake in shares of Fluidigm during the fourth quarter worth $102,000. Brown Advisory Inc. bought a new stake in shares of Fluidigm during the fourth quarter worth $115,000. Bank of America Corp DE lifted its position in shares of Fluidigm by 149.3% during the fourth quarter. Bank of America Corp DE now owns 14,449 shares of the medical research company’s stock worth $125,000 after purchasing an additional 8,654 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Fluidigm by 42.9% during the fourth quarter. Rhumbline Advisers now owns 34,489 shares of the medical research company’s stock worth $297,000 after purchasing an additional 10,358 shares during the last quarter. Institutional investors and hedge funds own 71.65% of the company’s stock.

About Fluidigm

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Featured Story: Depreciation

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.